Literature DB >> 24525229

Molecular subtyping of invasive bladder cancer: time to divide and rule?

Carolyn D Hurst1, Margaret A Knowles2.   

Abstract

Therapeutic decisions for muscle-invasive bladder cancer (MIBC) are largely based on histopathologic characteristics. In this issue of Cancer Cell, Choi and colleagues report three molecular subtypes of MIBC with the potential to guide prognosis, patient stratification, and treatment.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24525229     DOI： 10.1016/j.ccr.2014.01.026

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  13 in total

1.  Will the 40-gene expression classifier predict responders to EGFR targeted chemotherapy for the invasive bladder cancer patients?

Authors:  Jayoung Kim; Wun-Jae Kim
Journal:  Ann Transl Med       Date:  2015-02

2.  Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.

Authors:  Karsten Salomo; Doreen Huebner; Manja U Boehme; Alexander Herr; Werner Brabetz; Ulrike Heberling; Oliver W Hakenberg; Daniela Jahn; Marc-Oliver Grimm; Daniel Steinbach; Marcus Horstmann; Michael Froehner; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-08       Impact factor: 4.553

3.  OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.

Authors:  Michael Rose; Claudia Schubert; Laura Dierichs; Nadine T Gaisa; Matthias Heer; Axel Heidenreich; Ruth Knüchel; Edgar Dahl
Journal:  Epigenetics       Date:  2014-12       Impact factor: 4.528

4.  Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas.

Authors:  Feng He; Jonathan Melamed; Moon-Shong Tang; Chuanshu Huang; Xue-Ru Wu
Journal:  Cancer Res       Date:  2015-03-20       Impact factor: 12.701

Review 5.  Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena.

Authors:  Richard T Bryan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-02-05       Impact factor: 6.237

6.  Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism.

Authors:  Mohamed Elbadawy; Yomogi Sato; Takashi Mori; Yuta Goto; Kimika Hayashi; Megumi Yamanaka; Daigo Azakami; Tsuyoshi Uchide; Ryuji Fukushima; Toshinori Yoshida; Makoto Shibutani; Mio Kobayashi; Yuta Shinohara; Amira Abugomaa; Masahiro Kaneda; Hideyuki Yamawaki; Tatsuya Usui; Kazuaki Sasaki
Journal:  Cancer Biol Ther       Date:  2021-05-26       Impact factor: 4.875

Review 7.  Targeting Hsp90 in urothelial carcinoma.

Authors:  Mahmoud Chehab; Tiffany Caza; Kamil Skotnicki; Steve Landas; Gennady Bratslavsky; Mehdi Mollapour; Dimitra Bourboulia
Journal:  Oncotarget       Date:  2015-04-20

8.  FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.

Authors:  Haiping Zhou; Feng He; Cathy L Mendelsohn; Moon-Shong Tang; Chuanshu Huang; Xue-Ru Wu
Journal:  Sci Rep       Date:  2016-05-09       Impact factor: 4.379

Review 9.  Circulating Biomarkers in Bladder Cancer.

Authors:  Lakshminarayanan Nandagopal; Guru Sonpavde
Journal:  Bladder Cancer       Date:  2016-10-27

10.  Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines.

Authors:  Margaretha A Skowron; Günter Niegisch; Gerhard Fritz; Tanja Arent; Joep G H van Roermund; Andrea Romano; Peter Albers; Wolfgang A Schulz; Michèle J Hoffmann
Journal:  J Exp Clin Cancer Res       Date:  2015-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.